Zucara Therapeutics: Funding, Investors & Team (Sep 2026)
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.
Zucara Therapeutics has raised $27.0M across 4 funding rounds on record, the most recent a Series B of $5.0M announced in May 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Zucara Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2025.
Zucara Therapeutics Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
Zucara Therapeutics announced a Grant in May 2022; the amount was not disclosed.
1.1 years later, an undisclosed round of $2.0M was announced in Jun 2023.
1.4 years later, a Series B of $20.0M was announced in Nov 2024.
6 months later, a Series B of $5.0M was announced in May 2025.
Zucara Therapeutics Founders and Leadership Team
Contact details for the Zucara Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Zucara Therapeutics Funding Compared to Other Biotechnology Startups
Zucara Therapeutics' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Zucara Therapeutics in Biotechnology and Vancouver
Companies Similar to Zucara Therapeutics
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Zucara Therapeutics Funding FAQs
What does Zucara Therapeutics do?
Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically block somatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.
How much funding has Zucara Therapeutics raised?
Zucara Therapeutics has raised $27.0M across 4 rounds on record. The most recent is a Series B of $5.0M announced in May 2025.
When did Zucara Therapeutics last raise funding?
Zucara Therapeutics' most recent funding round on record is a Series B of $5.0M, announced in May 2025.
Who founded Zucara Therapeutics?
FundedIQ lists Richard Liggins (Founder) at Zucara Therapeutics.
Where is Zucara Therapeutics headquartered?
Zucara Therapeutics is based in Vancouver, British Columbia, Canada.
How many employees does Zucara Therapeutics have?
Zucara Therapeutics is in the 11-50 employee band.
How does Zucara Therapeutics' funding compare to other Biotechnology startups?
Zucara Therapeutics' latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Zucara Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Zucara Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.